Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEF0217 phase 2b trial in Down syndrome
2025-521013-10-00Phase 2Authorised
- Sponsor
- Aelis Farma
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in Down syndrome comparing AEF0217 with Placebo (2 arms). Primary endpoint: Vineland Adaptive Behavior Scales, Third Edition 9 subdomains normalized raw scores. Planned start Nov 2025; status: authorised.
02
Drugs
AEF0217
03
Conditions
Down syndrome
Beyond the preview
Go deeper on 2025-521013-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521013-10-00.